Cardinal Health, Inc. (CAH), headquartered in Dublin, Ohio, operates as a healthcare services and products company. Valued at$36.6 billion by market cap, the company’s services include pharmaceutical distribution, health-care product manufacturing, distribution and consulting services, drug delivery systems development, pharmaceutical packaging, automated dispensing systems manufacturing, and retail pharmacy franchising. Thehealthcare giant isexpected to announce its fiscalfirst-quarter earnings for 2026 before the market opens onThursday, Oct. 30.
Ahead of the event, analysts expect CAH to report aprofit of $2.21 per share on a diluted basis, up 17.6% from$1.88 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates in its last four quarterly reports.
-
‘It’s About to Go Up By a Billion Times’: Nvidia CEO Jensen Huang Says the Next ‘Industrial Revolution’ Is Already Here
-
‘The Smartest Investments We Can Possibly Imagine’: Nvidia CEO Jensen Huang Says OpenAI Will Be Worth Trillions, Rivaling Amazon and Meta
-
A Dogecoin IPO Is Coming, But This 1 DOGE Stock Belongs in the Doghouse
-
Our exclusive Barchart Brief newsletter is your FREE midday guide to what’s moving stocks, sectors, and investor sentiment – delivered right when you need the info most. Subscribe today!
For the full year, analysts expect CAH to report EPS of $9.45, up 14.7% from $8.24 infiscal 2025. Its EPS is expected to rise 12% year over year to $10.58 in fiscal 2027.
CAH stock has significantly underperformed the S&P 500 Index’s ($SPX)14.7% gains over the past 52 weeks, with sharesup 39% during this period. Similarly, it underperformed the Health Care Select Sector SPDR Fund’s (XLV)7.8% losses over the same time frame.
Cardinal Health’s shares dropped 7.2% on Aug. 12 following its mixed Q4 earnings report. Its adjusted EPS surged 13% to $2.08, beating estimates of $2.03. However, revenue of $60.2 billion slightly missed analyst expectations, despite a marginal year over year increase, likely eroding investor confidence.
Analysts’consensus opinion on CAH stock is bullish, with a “Strong Buy” rating overall. Out of 15 analysts covering the stock, 11 advise a “Strong Buy” rating, and four give a “Hold.” CAH’s average analyst price target is $179.80, indicating a potential upside of 15.5% from the current levels.
On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originallypublished on Barchart.com
